TICKER INTELLIGENCE
NYSE/NASDAQ: CAG
2
Active Bills
1
Gov't Contracts
50
Congressional Trades
$CAG is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 3 active Congressional signals mentioning $CAG, including 2 bills and 1 federal contract. The legislative sentiment is currently mixed, with both supportive and challenging policy signals in play.
⚠ Rep. Cisneros bought $1K-$15K in CRWD on May 15, 2026 — 5 days before HR8880 (a bill boosting cybersecurity for small businesses) was introduced.
⚠ System: No overlapping signals found
⚠ System: No overlapping signals found
⚠ System: No overlapping signals found
⚠ Gilbert Cisneros bought $100,001 - $250,000 in TSM on 2026-02-09, one day before S2722, the "Taiwan Energy Security and Anti-Embargo Act of 2026," advanced to the Senate Legislative Calendar, a bullish signal for the company.
⚠ System: No valid trades to analyze
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Gilbert Cisneros bought $1,001 - $15,000 in LMT on 2025-08-05, 56 days before the Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 (HR3838) was enacted, which significantly impacts defense contractors.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Gilbert Cisneros bought $15,001 - $50,000 in JNJ on 2025-05-30, 6 days before the 'Treat and Reduce Obesity Act of 2025' (S1973) was introduced, which aims to expand Medicare coverage for obesity treatments.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Johnson bought $1K-$15K in MRK on Jan 17, 2025 — 35 days before HR1492 was introduced, a bill extending Medicare price-negotiation protections for small-molecule drugs like those from Merck.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No valid trades to analyze
⚠ System: No valid trades to analyze
⚠ System: No valid trades to analyze
⚠ System: No suspicious timing patterns detected
⚠ System: No overlapping signals found
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
HR8431 is an early-stage bill that would expand the FDA's accredited third-party certification program for food safety audits. With zero funding authorization and no direct causal chain to any publicly traded company at this stage, it has no near-term market impact.
The FSMA Fee Technical Corrections Act is a procedural bill that adjusts FDA reinspection and recall fees to a $15,000 inflation-adjusted base for large food manufacturers starting FY2026. The bill is early-stage (referred to committee) with no market-moving impact. Real market data shows no correlation with this bill—the sector's 30-day declines (GIS -5.83%, CAG -9.35%, CPB -7.45%, HSY -11.38%) reflect broader consumer staples weakness, not legislative action.
→ Event-driven cost increase for any facility that triggers FDA reinspection or a recall order. Fee is immaterial relative to Conagra's revenue ($12B+ annually).
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →